3M to invest nearly $150 million on expanding biopharma filtration capabilities

The investment will include facility and equipment improvements and the addition of 60 full-time positions in 3M manufacturing facilities in Europe.

Gilead acquires XinThera to strengthen pipeline in oncology

Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors

FSD Pharma completes dosing of first cohort in Phase I clinical trial of Lucid-MS

Lucid-MS is a new drug candidate for the treatment of multiple sclerosis

PredOmix launches campaign for free cancer screening

PredOmix has developed a novel blood test that can detect about 32 cancers in both men and women with 98 percent accuracy

PI Industries announces twin acquisitions into Pharma API & CDMO space

Aurisco expands Oligonucleotide capacity

The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.

Taros Chemicals and Welab Barcelona partner for drug Discovery and development services

The combination will support clients in getting their end-to-end discovery and development programs delivered.

Thermo Fisher Scientific expands its capabilities in France

Bourgoin early development hub broadens offerings for oral solid dose formulations

Inflation and declining FDA drug approvals will pose challenges for pharma contract manufacturers in 2023, says GlobalData

FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop

Pfizer acquisition of ADC trailblazer Seagen a worthy investment: GlobalData

Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.